A detailed history of American Portfolios Advisors transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, American Portfolios Advisors holds 1,700 shares of BCRX stock, worth $12,920. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,700
Holding current value
$12,920
% of portfolio
0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023

BUY
$10.79 - $14.81 $18,343 - $25,177
1,700 New
1,700 $21.4 Million
Q3 2021

Mar 22, 2023

BUY
$14.21 - $17.65 $497,350 - $617,750
35,000 Added 2058.82%
36,700 $527 Million
Q2 2021

Mar 22, 2023

BUY
$9.5 - $17.24 $335,350 - $608,572
35,300 Added 2076.47%
37,000 $585 Million
Q1 2021

Mar 22, 2023

BUY
$7.37 - $13.61 $253,896 - $468,864
34,450 Added 2026.47%
36,150 $368 Million
Q4 2020

Mar 22, 2023

BUY
$3.37 - $8.61 $56,616 - $144,648
16,800 Added 988.24%
18,500 $138 Million
Q3 2020

Mar 22, 2023

BUY
$3.43 - $5.53 $202 - $326
59 Added 3.47%
1,759 $6.04 Million
Q2 2020

Mar 24, 2023

SELL
$1.9 - $5.61 $1,330 - $3,927
-700 Reduced 41.18%
1,000 $4.77 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.